A Ettengruber1, J Epple1, Th Schmitz-Rixen2, D Böckler3, R T Grundmann4,5. 1. Department of Vascular and Endovascular, Surgery University Hospital, Frankfurt am Main, Germany. 2. German Institute for Vascular Health Research (DIGG) of the German Society of Vascular Surgery and Vascular Medicine, Berlin, Germany. 3. Department of Vascular and Endovascular Surgery, University Hospital, Heidelberg, Germany. 4. German Institute for Vascular Health Research (DIGG) of the German Society of Vascular Surgery and Vascular Medicine, Berlin, Germany. grundmann@medsachverstand.de. 5. Department of Vascular Medicine, University Heart Center (UHC), University Hospital Hamburg-Eppendorf, Hamburg, Germany. grundmann@medsachverstand.de.
Abstract
PURPOSE: The influence of cancer development on long-term outcome after elective endovascular (EVAR) vs. open repair (OAR) of non-ruptured abdominal aortic aneurysms (AAA) was investigated. METHODS: Patient survival and cancer incidence were recorded for 18,802 patients registered with the AOK health insurance company in Germany who underwent EVAR (n = 14,218) and OAR (n = 4584) in the years 2010 to 2016 (men n = 16,086, women n = 2716). All patients were preoperatively and in their history cancer-free. RESULTS: 30.1% of EVAR and 27.6% of OAR patients (p ≤ .001) developed cancer after a follow-up period of up to 9 years (Kaplan-Meier estimated). Patients with cancer had a significantly less favorable outcome compared to patients with no cancer (HR 1.68; 95% CI 1.59-1.78, p < .001). After 9 years, the estimated survival of patients with and without cancer was 27.0% and 55.4%, respectively (p < .001). Survival of men and women did not differ significantly (HR 0.94; 95% CI 0.88-1.00, p = .061). In the Cox regression analysis (adjusted outcomes by operative approach, gender, age, and comorbidities), the postoperative cancer incidence was not significantly different between EVAR and OAR (HR 1.09; 95% CI 1.00-1.18, p = .051). However, EVAR showed an increased risk of postoperative development of abdominal cancer (HR 1.20; 95% CI 1.07-1.35, p = .002). 48.0% of all EVAR patients and 53.4% of all OAR patients survived in the follow-up period of up to 9 years. This difference was not significant (HR 0.96; 95% CI 0.91-1.02, p = .219). CONCLUSION: Cancer significantly worsened the long-term outcome after EVAR and OAR, without significant differences between the two repair methods in the overall cancer incidence. However, the higher abdominal cancer incidence with EVAR can affect quality of life including oncological therapy and therefore should be considered when determining the indication for surgery, and the patient should be informed about it.
PURPOSE: The influence of cancer development on long-term outcome after elective endovascular (EVAR) vs. open repair (OAR) of non-ruptured abdominal aortic aneurysms (AAA) was investigated. METHODS: Patient survival and cancer incidence were recorded for 18,802 patients registered with the AOK health insurance company in Germany who underwent EVAR (n = 14,218) and OAR (n = 4584) in the years 2010 to 2016 (men n = 16,086, women n = 2716). All patients were preoperatively and in their history cancer-free. RESULTS: 30.1% of EVAR and 27.6% of OAR patients (p ≤ .001) developed cancer after a follow-up period of up to 9 years (Kaplan-Meier estimated). Patients with cancer had a significantly less favorable outcome compared to patients with no cancer (HR 1.68; 95% CI 1.59-1.78, p < .001). After 9 years, the estimated survival of patients with and without cancer was 27.0% and 55.4%, respectively (p < .001). Survival of men and women did not differ significantly (HR 0.94; 95% CI 0.88-1.00, p = .061). In the Cox regression analysis (adjusted outcomes by operative approach, gender, age, and comorbidities), the postoperative cancer incidence was not significantly different between EVAR and OAR (HR 1.09; 95% CI 1.00-1.18, p = .051). However, EVAR showed an increased risk of postoperative development of abdominal cancer (HR 1.20; 95% CI 1.07-1.35, p = .002). 48.0% of all EVAR patients and 53.4% of all OAR patients survived in the follow-up period of up to 9 years. This difference was not significant (HR 0.96; 95% CI 0.91-1.02, p = .219). CONCLUSION: Cancer significantly worsened the long-term outcome after EVAR and OAR, without significant differences between the two repair methods in the overall cancer incidence. However, the higher abdominal cancer incidence with EVAR can affect quality of life including oncological therapy and therefore should be considered when determining the indication for surgery, and the patient should be informed about it.
Authors: Sheraz R Markar; Alberto Vidal-Diez; Viknesh Sounderajah; Hugh Mackenzie; George B Hanna; Matt Thompson; Peter Holt; Jesper Lagergren; Alan Karthikesalingam Journal: J Vasc Surg Date: 2018-12-21 Impact factor: 4.268
Authors: Ben Li; Shawn Khan; Konrad Salata; Mohamad A Hussain; Charles de Mestral; Elisa Greco; Badr A Aljabri; Thomas L Forbes; Subodh Verma; Mohammed Al-Omran Journal: J Vasc Surg Date: 2019-05-27 Impact factor: 4.268